Last updated: April 25, 2026
Allergan v. Alcon (2:09-cv-00348): Litigation Summary and Patent/Claim-Strategy Analysis
What dispute is captured in 2:09-cv-00348?
Allergan, Inc. v. Alcon Laboratories, Inc. (U.S. District Court for the Eastern District of Texas) is a patent infringement case filed in 2009 and docketed as 2:09-cv-00348. The dispute centers on ophthalmic products and method-of-use / composition-related patent claims asserted by Allergan against Alcon.
The specific asserted patents, claim chart details, and final judgment outcomes are not provided in the input record. Without those case-specific documents, the infringement issues cannot be mapped to particular claim elements, patent families, or adjudicated invalidity/construction outcomes.
What is the litigation posture and procedural arc?
The available information is limited to the case caption and docket number. The record does not include:
- asserted patent numbers
- claim construction orders
- infringement/invalidity rulings
- summary judgment disposition
- trial verdict terms
- damages rulings
- settlement terms or stipulated dismissal language
Without those facts, a complete procedural arc tied to outcomes (win/loss per patent, per claim, or per issue) cannot be produced.
What patents and claims were at issue?
A litigation analysis in a patent context requires at minimum:
- patent identifiers (e.g., USxxxxxxx)
- claim sets asserted at filing and at disposition
- the court’s claim construction (Markman) for key terms
- the final infringement and validity findings
The input does not include patent identifiers or substantive claim language. As a result, no reliable mapping to claim scope or adjudicated interpretations can be performed.
How should a business user interpret the litigation for R&D/IP strategy?
Given the absence of asserted-patent and decision-content details, only high-level interpretation is possible, and that is not suited to high-stakes R&D or investment decisions. A Bloomberg-style analysis must connect to hard holdings (claim construction results, infringement findings, invalidity grounds, estoppel or settlement-driven narrowing). That connection cannot be made from the provided inputs.
What can be stated from the available information:
- The matter is a 2009 Allergan v. Alcon patent dispute in federal court (E.D. Texas) under 2:09-cv-00348.
- The analysis cannot be extended into: which product(s) were accused, which claim elements drove the outcome, or which patent survived scrutiny.
Case outcomes, holdings, and enforceability conclusions
The input record does not provide the dispositive end state for docket 2:09-cv-00348. Without orders or final judgment text, the following cannot be stated:
- which patents were found infringed
- whether any asserted patents were invalidated
- whether claims were held not infringed due to non-corresponding limitations
- whether the court entered a permanent injunction
- whether the case ended via settlement or voluntary dismissal
- whether appeal occurred and what the appellate court decided
Operational impact: what would change for product development or freedom-to-operate?
A credible freedom-to-operate view requires at least one of:
- adjudicated claim scope constructions that narrow or expand coverage
- findings on whether key features (e.g., specific chemical forms, dosing regimens, formulation attributes, or device aspects) meet claim limitations
- final invalidity grounds (anticipation/obviousness) tied to references
Those inputs are not present. A defensible actionable recommendation for formulation or protocol development cannot be derived.
Key Takeaways
- Docket identified: Allergan, Inc. v. Alcon Laboratories, Inc., 2:09-cv-00348.
- No substantive record provided: asserted patents, claim constructions, infringement/invalidity rulings, and final disposition are not included, so a complete patent-claim litigation analysis cannot be produced from the provided information.
- No R&D actionable mapping possible: without the specific patent numbers and court holdings, claim element-level strategy and enforceability conclusions cannot be stated.
FAQs
-
What court and docket is this?
U.S. District Court, Eastern District of Texas; docket 2:09-cv-00348.
-
Who are the parties?
Allergan, Inc. (plaintiff) and Alcon Laboratories, Inc. (defendant).
-
What technology area is implicated?
The dispute is ophthalmic, but the exact product scope and asserted claims are not provided in the input record.
-
What was the outcome of the case?
The input record does not include the dispositive orders or judgment, so the outcome cannot be stated.
-
What does this mean for freedom-to-operate?
A claim-scope and invalidity-driven FTO assessment requires the asserted patents and court holdings, which are not provided here.
References (APA)
[1] Allergan, Inc. v. Alcon Laboratories, Inc., No. 2:09-cv-00348 (E.D. Tex.).
